It was first launched in the United States by the U . S . Food and Drug Administration ( FDA ) ( specifically at the 4 mg dose / strength ) for hay fever ( a . k . a . allergic rhinitis, SAR and PAR ); vasomotor rhinitis; mild urticaria; angioedema, dermatographism and allergic conjunctivitis.
